Filtered By:
Drug: Enbrel

This page shows you your search results in order of date. This is page number 3.

Order by Relevance | Date

Total 39 results found since Jan 2013.

Authors’ Reply to Whitlock: Perispinal Etanercept for Post-Stroke Neurological and Cognitive Dysfunction: Scientific Rationale and Current Evidence
Source: CNS Drugs - November 6, 2014 Category: Neurology Source Type: research

Comment on: “Perispinal Etanercept for Post-Stroke Neurological and Cognitive Dysfunction: Scientific Rationale and Current Evidence”
Source: CNS Drugs - November 6, 2014 Category: Neurology Source Type: research

Tumor necrosis factor-{alpha} inhibition attenuates middle cerebral artery remodeling but increases cerebral ischemic damage in hypertensive rats
Hypertension causes vascular inflammation evidenced by an increase in perivascular macrophages and proinflammatory cytokines in the arterial wall. Perivascular macrophage depletion reduced tumor necrosis factor (TNF)-α expression in cerebral arteries of hypertensive rats and attenuated inward remodeling, suggesting that TNF-α might play a role in the remodeling process. We hypothesized that TNF-α inhibition would improve middle cerebral artery (MCA) structure and reduce damage after cerebral ischemia in hypertensive rats. Six-week-old male stroke-prone spontaneously hypertensive rats (SHRSP) were treated ...
Source: AJP: Heart and Circulatory Physiology - September 1, 2014 Category: Cardiology Authors: Pires, P. W., Girgla, S. S., Moreno, G., McClain, J. L., Dorrance, A. M. Tags: VASCULAR BIOLOGY AND MICROCIRCULATION Source Type: research

Rapidly Fatal Internal Carotid Artery Mycotic Aneurysm Rupture in a Rheumatoid Patient Taking a TNF-α Inhibitor: Case Report and Literature Review
Conclusions Although fungal mycotic aneurysms of the ICA are rare, their incidence may increase with the expanded use of immunosuppressive medications. Patients with rheumatoid arthritis who take potent immunosuppression regimens may be prime candidates for mycotic aneurysms because they often have two favoring conditions: atherosclerosis and immunosuppression. These ICA aneurysms carry a high mortality rate, so early diagnosis and aggressive therapy, potentially by endovascular trapping/vessel occlusion coupled with long-term antifungal therapy, is essential.[...]Georg Thieme Verlag KG Stuttgart · New YorkArticle in Th...
Source: Journal of Neurological Surgery Part A: Central European Neurosurgery - July 21, 2014 Category: Neurosurgery Authors: Bowers, Christian A.Saad, DanyClegg, Daniel O.Ng, PerryClayton, FredericHaydoura, SouhaSchmidt, Richard H. Tags: Case Report Source Type: research

Tumor necrosis factor-alpha inhibition attenuates middle cerebral artery remodeling but increases cerebral ischemic damage in hypertensive rats.
Abstract Hypertension causes vascular inflammation evidenced by an increase in perivascular macrophages and proinflammatory cytokines in the arterial wall. Perivascular macrophages depletion reduced tumor necrosis factor (TNF)-α expression in cerebral arteries of hypertensive rats and attenuated inward remodeling, suggesting that TNF-α might play a role in the remodeling process. We hypothesized that TNF-α inhibition would improve middle cerebral artery (MCA) structure and reduce damage after cerebral ischemia in hypertensive rats. Six-week-old male stroke-prone spontaneously hypertensive rats (SHRSP) were trea...
Source: American Journal of Physiology. Heart and Circulatory Physiology - July 11, 2014 Category: Physiology Authors: Pires PW, Girgla SS, Moreno G, McClain JL, Dorrance AM Tags: Am J Physiol Heart Circ Physiol Source Type: research

Anti glutamic acid decarboxylase antibody mediated encephalopathy while on etanercept in a patient with multiple autoimmune diseases
A 39 year old lady presented with an altered mental state and unsteadiness of gait. She had a history of juvenile idiopathic arthritis, autoimmune thyroiditis and alopecia, protein S deficiency with vena cava thrombosis, previous excision of ovarian mass and vasculitic rash. There was a previous history of ovarian mass and her immunomodulatory therapy for arthritis over the previous year was Etanercept. She used recreational cannabis but denied any other illicit drug usage. Her affect was variable and at times inappropriate with frequent laughter. She would spit regularly. There was anxiety and a prevailing sensation of do...
Source: Journal of Neurology, Neurosurgery and Psychiatry - October 9, 2013 Category: Neurosurgery Authors: MacDougall, N., Waddell, B., O'Riordan, J. I. Tags: Immunology (including allergy), Brain stem / cerebellum, Drugs: CNS (not psychiatric), Epilepsy and seizures, Infection (neurology), Stroke, Drugs misuse (including addiction), Connective tissue disease, Musculoskeletal syndromes Association of British Source Type: research

Stroke Treatments with Perispinally Administered Etanercept...
South Florida Sun Sentinel recently published reports of amazing stroke recoveries.* Neurological Wellness Center Physician Augusto Ramirez M.D. confirms similar outcomes.(PRWeb July 17, 2013)Read the full story at http://www.prweb.com/releases/2013/7/prweb10903745.htm
Source: PRWeb: Medical Pharmaceuticals - July 18, 2013 Category: Pharmaceuticals Source Type: news

A comparison of etanercept vs. infliximab for the treatment of post-arrest myocardial dysfunction in a swine model of ventricular fibrillation
Conclusions: Only infliximab demonstrated a beneficial effect on post cardiac arrest hemodynamics and LV function in this swine model. Etanercept was no better in this regard than saline.
Source: Resuscitation - January 11, 2013 Category: Emergency Medicine Authors: Scott T. Youngquist, James T. Niemann, Atman P. Shah, Joseph L. Thomas, John P. Rosborough Tags: Experimental Source Type: research

Neurological Wellness Center Pays Tribute to Newly Released Study...
An observational study involving 629 subjects finds rapid, significant, readily-observable improvement in stroke and traumatic brain injury patients following the perispinal administration of Enbrel.(PRWeb January 02, 2013)Read the full story at http://www.prweb.com/releases/2013/1/prweb10268871.htm
Source: PRWeb: Medical Pharmaceuticals - January 2, 2013 Category: Pharmaceuticals Source Type: news